Kornimate/medical-research-clean huggingface dataset:
screening for delirium in older inpatients

Conditions: Delirium in Old Age

Summary: two-arm parallel-randomized pilot study and to collect data at the department of geriatric medicine at aalborg university hospital. the aim is to assess the feasibility of a future randomized controlled study comparing danish versions of 3d-cam and 4at in an acute medical setting. the primary objective is to assess 1) feasibility of obtaining informed consent and recruiting older adults within 24 hours of admission (or surgery) at the department of geriatric medicine, department of acute medicine, or department of orthopedic surgery. secondary objectives are 2a) to compare feasibility of recruitment and testing in the three different departments, 2b) to inform a preliminary evaluation of validity and reliability of the danish version of screening instruments, and 2c) to obtain data on variance to support calculating sample size for a full-scale rct.

we will recruit participants through a consecutive sampling of all potentially eligible patients. recruitment will take place in three different settings: the department of geriatric medicine, the department of acute medicine, and the department of orthopedic surgery. one week will be allocated for recruitment in each setting. potentially delirious patients often have impaired cognitive status. therefore, the process of recruitment and informed consent is critically important and poses a central issue of feasibility to be assessed in this study. it cannot be known with certainty whether patients are delirious prior to inclusion into the study, and even among delirious patients, there are considerable circadian fluctuations (as this is a hallmark of the condition), meaning that patients may have lucid moments during the day where they are cognitively intact and may be able to give informed consent. generally, informed consent will be sought from participants when possible. in case they are permanently or temporarily unable to give informed consent, informed consent will be sought from next of kin. due to the short time in the study for each participant, it is not anticipated that participants will regain the ability to give informed consent during the study. however, if they do, new informed consent will be obtained from the participant. the number of potential participants at each step will be documented to assess problems with feasibility.

Eligibility criteria:
inclusion criteria: * age over 80 years * admission or surgery within the last 24 hours exclusion criteria: * unable to obtain contact to next of kin for informed consent within time-frame
anticholinergic premedication induced fever in pediatric ambulatory anesthesia with ketamine

Conditions: Fever

Summary: anticholinergic drugs have traditionally been used for their antisialagogue properties. but use of anticholinergic drugs can interfere with thermoregulation via inhibition of the parasympathetically mediated sweat secretion. sweating inhibition can reduce heat elimination, and children's thermoregulation depend more on sweating than adults and they can become hyperthermic when given these agents. the investigators evaluated the fever-causing effects of adjunctive anticholinergics in children under general anesthesia using ketamine.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status classification i * underwent surgery between 8 to 9 am * undergoing ambulatory anesthesia with ketamine exclusion criteria: * who required endotracheal intubation * who were administered with medications other than ketamine

Keywords: child outpatient premedication
effect of peri-operative glucocorticoids on short-term functional outcome after tha

Conditions: Coxarthrosis; Avascular Necrosis of Hip

Summary: this randomized, single surgeon, placebo controlled, double blind study will be conducted in order to investigate whether or not peri-operative high doses of intravenous glucocorticoids improve short-term functional outcome after direct anterior total hip arthroplasty. so far, it has been proven that high dose glucocorticoids reduce immediate post-operative pain and nausea, but no data exists on functional outcome during the first 6 weeks. our hypothesis is that patients in the intervention group will follow a so-called "get ahead, stay ahead" principle and that glucocorticoids can be considered an important tool (adjuvant treatment) in the enhanced recovery pathway after tha with significant socio-economic implications.

patients listed for a direct anterior total hip arthroplasty by a single surgeon will be recruited for this study and allocated to one of two groups: 1. intervention group: 25 grams of iv dexamethasone at induction followed by 10 mg of iv dexamethasone 12 hours later 2. control group: 5 grams of iv dexamethasone at induction followed by placebo 12 hours later both patients and surgeons will be blinded. primary outcome measure will be number of steps during the first 6 weeks as measured by a pedometer. secondary outcome measures will be side effects, complications, patient reported outcome measures, pain, nausea, stiffness, achievement of clinical milestones and use of analgesia/anti-emetics. this data will be collected using a tailor made application for a smartphone or tablet and data collecting will start one week before surgery until 6 weeks after surgery. based on a power analysis both groups will consist of 35 patients each.

Eligibility criteria:
inclusion criteria: * all patients undergoing unilateral uncemented tha for primary oa or avn of the hip under general anesthesia (ga) * aged 18 years and above (including women of child bearing age) * able to provide informed consent exclusion criteria: * younger than 18 years * known alcohol or drug abuse * known allergy for glucocorticoids * administration of any glucocorticoids in the last three months * usage of strong analgesia (such as lyrica or oxycodone) as regular medication * usage of medication with anticipated interactions with glucocorticoids * known gastric ulcer * insulin dependent diabetes mellitus * severe heart disease (nyha \> 2) * liver or renal failure * systemic rheumatoid diseases * insufficient understanding of the dutch language * unable to provide informed consent * pre-operative use of walking aids * gross anatomical deformities * significant intra-operative complications such as periprosthetic fracture

Keywords: total hip arthroplasty direct anterior approach glucocorticoids short term functional outcome
flibanserin for the treatment of hypoactive sexual desire disorder in postmenopausal women

Conditions: Sexual Dysfunctions, Psychological

Summary: the objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of hypoactive sexual desire disorder (hsdd) in naturally postmenopausal women.


Eligibility criteria:
inclusion criteria: * naturally postmenopausal women of any age with at least one ovary * diagnosis of hypoactive sexual desire disorder, generalized acquired type,of at least six months duration * stable, monogamous heterosexual relationship for at least one year * willing to discuss sexual issues * willing to engage in sexual activity at least once a month * normal pap smear * normal mammogram * normal uterine lining * able to comply with daily use of handheld data entry device exclusion criteria: * sexual dysfunctions other than hsdd, such as sexual aversion disorder, substance-induced sexual dysfunction, dyspareunia, vaginismus, gender identity disorder, paraphilia and sexual dysfunction due to a general medical condition * partner with inadequately treated organic or psychosexual dysfunction * sexual function impaired by psychiatric disorder * sexual function impaired by gynecological disorder * major depression * suicidal behavior or ideation * major life stress that could impair sexual function * substance abuse
spatial epidemiology of hiv infection

Conditions: HIV Infections; Acquired Immunodeficiency Syndrome

Summary: data will be extracted from the national taiwan university hospital (ntuh) medical records database, geocoded according to the street address so that the case number, incidence, etc could be mapped. the spatial data would be used to detect the aggregation of hiv cases, existence of "hot spots" and then determine if they may merit further investigation or may have occurred by chance. the results from these gis-based analyses would address local variations in hiv prevalence and transmission.

the transmission routes of human immunodeficiency virus (hiv) are well known and many control programs focusing on risk groups and behavior have been undertaken. however, the risk factors of hiv transmission are not only at individual level (eg: demographic, behavior, and genetic risk factors), socioeconomic and environmental factors also take important roles. in taiwan, few researches explored the spatial distribution of hiv infection. studies in other countries observed a significant geographic variation in hiv infection. to understand the spatial pattern of hiv infection in depth, the present study aims to retrospectively investigate the epidemiological and geographic characteristics of hiv infection using the medical records database of national taiwan university hospital. a geographic information system (gis) and spatial statistics will be used to analyze the geographic patterns to determine whether spatial dispersion or clustering. there are two aims of this study. one is to investigate the epidemiology of hiv infection in taipei city. the second is to analyze the spatial characterizes of hiv infection, including disease mapping, geographic correlation studies, and identifying the presence of hiv clusters and their potential spatial risk factors. in addition, we want to examine whether there are different distributions between different classificatory groups. finally, we hope that our findings would give some direction for local health and policy planners to improve the hiv intervention and prevention strategies

Eligibility criteria:
inclusion criteria: * hiv/aids patients of ntuh exclusion criteria: * hiv/aids patient whose address cannot be geocoded

Keywords: hiv/aids spatial epidemiology geographic information system hiv-infection/aids
carotid body removal for the treatment of resistant hypertension

Conditions: Hypertension

Summary: this is a pilot study to assess the effectiveness, safety and feasibility of carotid body removal in patients with high blood pressure (hypertension) resistant to medical treatment. patients with high blood pressure are at significant risk of medical complications including stroke and heart disease. the principle research question is whether removal of the carotid body will lead to an improvement in the blood pressure of this patient group.


Eligibility criteria:
inclusion criteria: * age of participants will be 18-75 years * resistant htn criteria: 1. daytime mean ambulatory systolic blood pressure ≥135mmhg and office systolic blood pressure ≥150mmhg 2. patients on at least three anti-hypertensive medications, including a diuretic, at maximum tolerated dose 3. no evidence of causes for secondary htn following thorough clinical assessment 4. patient medication concordance will be monitored via medication/blood pressure diary exclusion criteria: * calculated gfr \<45ml/min/1.73m2 * carotid body located outside the defined carotid septum * obstructive carotid atherosclerotic disease with \>50% stenosis * oxygen desaturation at rest below 92% * known structural lung disease * requirement for oxygen therapy to maintain oxygen saturation * patients wish to participate in mountain climbing, skin diving or free diving * pregnancy or anticipation of pregnancy * palliative care/chemotherapy * acute coronary syndrome or unstable angina * stroke or transient ischaemic attack (tia) \< 6 months prior to procedure * expected life expectancy less than 12 months due to other disease * intravenous drug use * alcohol intake \>28 units/week * febrile illness within two weeks of participation * unable to attend for follow up appointments in bristol at 1, 3, 6, 12 and 24 months post-operatively. mr imaging related exclusion criteria (all participants): * pace-maker, implantable cardiac defibrillator, cerebral metallic clips or other implanted metal devices/structures * unable to tolerate scanner or history of panic attacks/claustrophobia * learning disability, significant hearing or visual impairment (participant would need to able to communicate from within the mri scanner)
percutaneous needle electrolysis on metatarsalgia

Conditions: Metatarsalgia

Summary: percutaneous electrolysis is a minimally invasive method that involves the application of a galvanic current through an acupuncture needle. the needle is placed directly into the soft tissue structures, essential with ultrasound guidance. this technique involves the combination of mechanical stimulation produced by the needle and electrical/biochemical stimulation provided by the electrical current. endogenous pain modulation shows clinical relevance of this technique and plays an important role in the experience of pain. plantar plate injury is a pathology that frequently occurs in the forefoot, especially in middle-aged women, causing metatarsalgia that is sometimes very intense. in most cases it is secondary to a mechanical imbalance of the forefoot, related to an insufficiency of the first radius. for this reason, the researchers hypothesize that the application of ultrasound-guided percutaneous electrolysis on the plantar plate, combined with the conservative treatment consisting of the development of a personalized plantar orthosis, can cause positive effects in the patient's clinic as well as improve their quality of life.


Eligibility criteria:
inclusion criteria: * adult female patients (40-65 years old) * having pain in the 2nd mtp joint of the foot due to pathology of the plantar plate, diagnosed by a specialized professional. exclusion criteria: * to have suffered an injury to their musculoskeletal system in the last 6 months. * to have the present neuritic pathology, * to have complete rupture of the plantar plate, 2nd finger supraadductus, flexor digitorum longus tenosynovitis, * to have problems in the lumbar spine, * to have undergone surgery in the lumbar spine or lower limbs. * to use a plantar orthosis. * to have the presence of associated pathologies in the foot, * to be under the influence of any medication at the time of the study, fear of needles * to be pregnant * to be epileptic.
effect of a potent inducer rifampicin on the pharmacokinetics of deferasirox in healthy volunteers

Conditions: Healthy

Summary: the study will consist of two open-label periods, a treatment period i (deferasirox) and a treatment period ii (rifampicin+deferasirox). at least 18 subjects are expected to complete both treatment periods as per protocol. for all subjects, in addition to the two treatment periods, there will be a 21 day screening period, one baseline evaluation (the day preceding deferasirox administration in treatment period i), and an end-of-study evaluation (eos). study subjects will be required to remain in the unit from day -1 until day 17. eos evaluation (final safety assessment) will be performed 7-10 days after the last dose of rifampicin.


Eligibility criteria:
inclusion criteria 1. able and willing to provide written informed consent prior to study participation 2. male subjects from 18 - 45 years of age in good health and no evidence of iron deficiency. subjects of reproductive potential must use barrier contraception throughout the trial. 3. able to communicate well with the investigator and comply with the requirements of the study 4. subjects must have a body mass index (bmi) between 18 and 33. 5. serum ferritin value ≥20 ng/ml and transferrin saturation (iron/tibc) ≥15% at screening exclusion criteria 1. history or presence of impaired renal function 2. abnormal serum electrolytes (e.g. sodium, potassium, chloride, or bicarbonate), magnesium and calcium 3. evidence of urinary obstruction or difficulty in voiding at screening 4. anemia (defined as hemoglobin \< 13 g/dl) 5. a positive hepatitis b surface antigen (hbsag) or hepatitis c test result at screening 6. subjects with a known history of hiv seropositivity or history of immunocompromise 7. a past medical history of any ecg abnormalities or a family history of a prolonged qt-interval syndrome 8. donation or loss of 400 ml blood or more within 12 weeks prior to dosing 9. smokers (use of tobacco products in the previous 3 months). \* other protocol-defined inclusion/exclusion criteria may apply

Keywords: pharmacokinetics deferasirox exjade icl670 rifampicin healthy, volunteers
project hypnos: the impact of a brief hypnosis intervention on single-limb dynamic balance in people with chronic ankle instability

Conditions: Ankle Sprains; Motor Coordination or Function; Developmental Disorder

Summary: this study will determine the relationship of one's self-reported awareness of their body and their ankle motor control for people with chronic ankle instability. this study will further identify the correlates between certain psychological characteristics (i.e., fear and anxiety) and autonomic nervous system arousal (i.e., heart rate variability). furthermore, this study will elucidate the potential impact of a brief hypnosis practice on balance performance.


Eligibility criteria:
inclusion criteria: * history of one significant ankle sprain * experiences of instability in the ankle, determined by a score of \> 11 on the identification of functional ankle instability (idfai) questionnaire * an overall sensation of disability, determined by a score of \< 90% on the functional ankle ability measure (faam) questionnaire exclusion criteria: * if the participant's initial ankle sprain was within the past twelve months or the most recent ankle sprain was within the past three months, the participant was excluded from eligibility * a history of lower extremity surgery * a fracture to the lower extremity * any acute musculoskeletal injuries to lower extremities in the past three months

Keywords: interoceptive awareness heart rate variability anxiety
healthy aging team supported home-care services (heat-yasam)

Conditions: Frailty; Dementia; Depression; Malnutrition; Old Age; Debility; Drug Use

Summary: depending on the yasam project which was established to home-visit evaluate community-dwelling older adults (80 years of age and over), we aimed to determine the prevalence (prevalence) of geriatric syndromes (dependence, frailty, malnutrition, depression, dementia, comorbidity burden, polypharmacy) in these individuals and to determine possible changes in the follow-up of the patients during the 2-year follow-up period. (heaven trial)

individuals over the age of 80 who will participate in the yasam project will first be informed by phone and their appointments will be made. subsequently, a home visit will be conducted after obtaining verbal and written consent from the patients and their relatives. the chronic diseases and medications of the patients will be questioned and controlled from the electronic data set. to determine the level of frailty and dependency, the katz, lawton-brody, and clinical frailty scales will be filled in, respectively, by the previously trained health personnel, by interviewing their relatives. mini-cog, mini mental status assessment, mini nutrition assessment, and geriatric depression (yesavage) assessments will be planned. according to dependency status, individuals will be re-evaluated in the 1st or 2nd month. if the patients are fully independent, control follow-up is planned in the 3rd month. written file records will be created by obtaining the consent of the patients and their relatives at each patient visit. each team will be responsible for the follow-up of 300 patients. it is planned to include a total of 6000 individuals in the first phase, which is carried out in 20 centers throughout the province of balıkesir and whose coordination center is atatürk city hospital. in the follow-ups, it is planned to include the whole cohort consisting of 40 thousand individuals over the age of 80, by increasing the number of teams. the short-term results of the patient's follow-up (1st, 3rd, and 6th-month results), changes in mortality, addiction, frailty level, and changes in nutrition and cognitive functions within the specified period will be evaluated as short-term results. it is aimed to record the long-term outcomes (1st and 2nd year) of the same variables. since the whole population will be included in the study, sample size and power analysis were not performed.

Eligibility criteria:
inclusion criteria: * 80 years and over older adults * individuals giving verbal and written consent for the yasam project exclusion criteria: * \<80 years older adults * those who did not give verbal and written consent for the yasam project
immunogenicity and safety study of lbvh0101 in healthy infants at two, four and six months of age

Conditions: Infectious Disease by Haemophilus Influenzae Type b

Summary: the purpose of this study is to evaluate and compare the immunogenicity and safety of lbvh0101 (haemophilus influenzae type b tetanus toxoid conjugate vaccine) to that of hiberix™ at vaccination in healthy infants at their 2, 4, and 6 months of age.


Eligibility criteria:
inclusion criteria: * healthy male or female infants aged from 49 days to 84 days at the time of enrollment. * the gestation period was 37 weeks or longer, and birth weight was 2.5 kg or more. * the infants and their parents/legally acceptable representative could comply with all of the scheduled visits in the study and the study requirements related to protocol compliance. * the parents/legally acceptable representative (lar) signed the written consent form. exclusion criteria: * had previously received haemophilus influenzae type b vaccine prior to this clinical study. * had a plan for vaccination with the vaccine other than those permitted in the protocol based on the standard vaccination schedule. * had been contacted with a patient with confirmed hib infection within 30 days before the study start. * had had fever of ≥ 37.5°c within the last 3 days (if measured by tympanic thermometer, fever of 38°c or higher) * had or were suspected for immune function disorders; had previously received or were suspected to receive the immunosuppressive therapy; or had received the immunosuppressive therapy within 30 days prior to participating in the study (including systemic corticosteroids or inhalation corticosteroids) (however, it was not the exclusion criteria to have received corticosteroid therapy (prednisolone equivalent ≤ 0.5 mg/kg/day) not more than for 14 consecutive days at least 30 days before their participation in the study). * had received the treatment of parenteral immunoglobulin or blood products after birth. * had allergic history to be considered due to any component of the vaccine including excipients or preservatives. * three preceding generations in an ancestral line were not of korean heritage. * had or were suspected to have significant disorders of blood, heart, liver, kidney, nervous system, respiratory system, or digestive system, or the investigator decided that the evaluation of study objective might be interrupted. * had been treated with other investigational drug by participating in another clinical trial within 30 days prior to this study entry, or were participating in another clinical study at that time. * had plans to move away from the area of the study site before completing the study. * inappropriate to take part in this clinical study in the principal investigator or sub-investigator's opinion, for the reasons other than above criteria.